CHRONIC MYELOMONOCYTIC LEUKEMIA

This study tests the drug ruxolitinib (Jakafi) in 29 people with chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if the drug can improve blood counts, shrink the cancer, or delay its turning into a more aggressive leukemia. Researchers are also che…

This phase 2 trial tests whether adding the drug pomalidomide to standard chemotherapy (daunorubicin and cytarabine liposome) helps people with a newly diagnosed, aggressive form of acute myeloid leukemia (AML) linked to prior bone marrow disorders. About 50 participants will rec…

This phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…

This study was designed to test whether adding olutasidenib to standard chemotherapy drugs could help control certain blood cancers in people with an IDH1 gene mutation. The trial was withdrawn before enrolling any participants, so no results are available.

This study tests a combination of two drugs, venetoclax and ASTX727, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) who haven't had treatment before. The goal is to find the safest dose and see if the combo can shrink or control …

This phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…

This study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…

This study compares the standard drug azacitidine alone versus azacitidine combined with either lenalidomide or vorinostat in 282 patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The goal is to see if any combination improves re…

This phase 3 trial compares two treatments for people with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). One group gets lenalidomide alone, the other gets lenalidomide plus epoetin alfa, a drug that stimulates red blood …

This study tests a combination of two chemotherapy drugs (CPX-351 and gemtuzumab ozogamicin) in about 50 adults with acute myeloid leukemia (AML) that has returned or not responded to treatment, or with high-risk myelodysplastic syndrome (MDS). The goal is to see if the combo is …

This study tests whether adding venetoclax to ASTX727 (a two-in-one pill) works better than ASTX727 alone for people with chronic myelomonocytic leukemia or related bone marrow cancers with too many immature cells. About 132 adults will be randomly assigned to one of the two trea…

This early-phase trial is testing a drug called AZD6738 in 52 people with myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease got worse after standard therapy. The drug works by blocking a DNA repair pathway that cancer cells rely on, causing th…

This study tests whether combining two drugs, azacitidine and quizartinib, can help people with myelodysplastic syndromes or related blood cancers that have specific genetic changes (FLT3 or CBL mutations). The trial involves 30 adults and aims to find the best dose and see how w…

This study tests a new drug called bexmarilimab, given together with standard treatments, for people with certain blood cancers (MDS, CMML, or AML). The goal is to first find a safe dose and then see if the combination helps shrink or control the cancer. About 181 adults are taki…

This study tests a combination of two drugs—tagraxofusp and decitabine—in people with chronic myelomonocytic leukemia or high-risk myelodysplastic syndromes. Tagraxofusp is a targeted therapy that delivers a toxin to cancer cells, while decitabine is a chemotherapy drug. The tria…

This study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…

This phase 1 trial tests whether the oral drug Inqovi (decitabine/cedazuridine) can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will …

This early-stage trial tests the safety and best dose of combining two drugs—everolimus and midostaurin—for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is hard to treat. The drugs work by blocking faulty signals that help cance…

This early-phase trial tests a combination of three drugs—azacitidine, venetoclax, and pevonedistat—in adults newly diagnosed with a challenging form of acute myeloid leukemia (AML). The goal is to find the best dose and see if the combo can improve remission rates. About 40 part…

This study tests a combination of two drugs, azacitidine and venetoclax, in people with a high-risk form of chronic myelomonocytic leukemia (CMML). The goal is to see if the combo can shrink or control the cancer better than current treatments. About 44 adults will take part, and…

This study tests whether a geriatric assessment—looking at thinking, mobility, mood, nutrition, and medications—can help doctors choose the right transplant intensity for patients aged 60 and older with myeloid blood cancers. The goal is to reduce deaths from transplant complicat…

This early-stage trial aimed to test a combination of two drugs—ASTX727 (already approved for some blood cancers) and ASTX029 (an experimental ERK inhibitor)—in adults with myelodysplastic syndromes (MDS) or related blood cancers that have a mutation in the RAS pathway. The goal …

This study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…

This study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…

This early-phase study tests two drugs—guadecitabine and atezolizumab—together in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or not responded to prior therapy. The goal is to find the safest dose and see if the combination can shrin…

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This early-phase trial tests a combination of two treatments for people whose myeloid blood cancer (like AML or MDS) has returned after a matched stem cell transplant. The treatments are a specially processed donor immune cell infusion and an immunotherapy drug called ipilimumab.…

This study tests two drugs—omacetaxine and azacitidine—given together to people with untreated high-grade myelodysplastic syndromes (MDS), a serious bone marrow condition. The first part finds the safest dose of omacetaxine, and the second part checks how many patients achieve re…

This phase 2 trial tests giving two chemotherapy drugs, clofarabine and melphalan, before a donor stem cell transplant in 72 patients with leukemia or myelodysplastic syndrome in remission. The goal is to prevent the cancer from coming back after the transplant while causing fewe…

This study offers continued treatment with the drug ASTX727 to adults with acute myeloid leukemia, chronic myelomonocytic leukemia, or myelodysplastic syndromes who were already benefiting from it in earlier studies. The main goal is to monitor long-term safety. About 332 partici…

This study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Over 6 months, participants use a smartphone app to answer weekly quality-of-life questions and take photos of their fingernails or eyelids. Researchers aim …

This study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy donors in the lab. However, the study was withdrawn before any parti…

This study follows 144 blood cancer patients undergoing stem cell transplants to see how muscle function changes and whether it predicts complications like infections, relapse, or survival. Researchers will measure muscle mass and track medical events over time. The goal is to un…